コーパス検索結果 (1語後でソート)
通し番号をクリックするとPubMedの該当ページを表示します
1 acarbazine, IL-2 9 MU/m(2)/d for 4 days, and interferon alfa-2b).
2 he adverse effects were similar to those for interferon alfa-2b.
3 apy consisting of CVD plus interleukin-2 and interferon alfa-2b.
4 atment and after follow-up, as compared with interferon alfa-2b.
5 only complicates treatment with the cytokine interferon alfa-2b.
6 who are candidates for adjuvant therapy with interferon alfa-2b.
7 nfection were treated with standard doses of interferon alfa-2b.
8 nt with oral cimetidine (15% vs 5%), topical interferon alfa-2b (0% vs 1%), cryotherapy (0% vs 3%), p
10 odeficiency virus were randomized to receive interferon alfa-2b (3 million units 3 times a week) plus
11 two doses of CIFN (3 microg and 9 microg) or interferon alfa-2b (3 million units [MU]) weekly for 24
12 through 5 and as a bolus on days 12 and 19), interferon alfa-2b (3 million units subcutaneously three
13 ng either consensus interferon (9 microg) or interferon alfa-2b (3 million units) given three times w
16 sis that the combination of tremelimumab and interferon alfa-2b acting via different and possibly syn
17 mes a week) plus ribavirin (1,000 mg/day) or interferon alfa-2b alone for 48 weeks with 24 weeks of p
19 chronic hepatitis C to receive standard-dose interferon alfa-2b alone or in combination with ribaviri
20 ed in 3 published clinical trials evaluating interferon alfa-2b alone or with ribavirin either as ini
21 pared the efficacy and safety of recombinant interferon alfa-2b alone with those of a combination of
23 s C (n = 103) were treated for 24 weeks with interferon alfa 2b and followed up for 24 weeks after ce
25 l of 1,744 patients with HCV received either interferon alfa-2b and placebo or combination interferon
26 We believe that combination treatment of interferon alfa-2b and retinoic acid may offer a superio
28 rly virologic response [EVR]) with pegylated interferon alfa-2b and ribavirin (PEG/R) in identifying
29 nterferon alfa-2b and placebo or combination interferon alfa-2b and ribavirin for 24 or 48 weeks.
30 alfa-2b alone with those of a combination of interferon alfa-2b and ribavirin for the initial treatme
31 he efficacy, safety, and pharmacokinetics of interferon alfa-2b and ribavirin in children with chroni
32 For chronic hepatitis C, the combination of interferon alfa-2b and ribavirin is the treatment of cho
34 ated the activity of combined treatment with interferon alfa-2b and sorafenib, a Raf and multiple rec
35 ll-known antiangiogenic agents (minocycline, interferon alfa-2b, and fumagillin) and were stored for
37 e, vinblastine, cisplatin, decrescendo IL-2, interferon alfa-2b, and tamoxifen was repeated at 21-day
38 evoflurane, the combination of ribavirin and interferon alfa-2b, and various betamethasone-containing
41 (on days 5 to 8, 17 to 20, and 26 to 29) and interferon alfa-2b by subcutaneous injection (on days 5
42 atitis B, treatment with a 4-month course of interferon alfa-2b can achieve hepatitis B e antigen ser
44 ssigned to receive standard-dose recombinant interferon alfa-2b concurrently with ribavirin (1000 to
45 either the standard three-times-weekly (TIW) interferon alfa-2b dose (3 MIU) or the once-weekly (QW)
47 mination prior to a single 6-month course of interferon alfa-2b; empirical interferon treatment; and
48 nts receiving a combination of ribavirin and interferon alfa-2b experienced an increased incidence of
51 ompared peginterferon alfa-2b (PegIntron) to interferon alfa-2b for the initial treatment of compensa
52 he efficacy, safety, and timing of pegylated interferon alfa-2b for treatment of acute hepatitis C.
53 e rates to 3, 5, or 10 million units (MU) of interferon alfa-2b, given thrice weekly, and to determin
55 therapeutic agents such as interleukin-2 and interferon alfa-2b has been reported to provide improved
62 cted with HIV and HCV to receive 48 weeks of interferon alfa-2b (IFN) 3 million units three times wee
63 /m2, 5-FU 640 mg/m2/d as a 120-hour CIV, and interferon alfa-2b (IFN) at 2 MU/m2/d for 6 days for thr
65 for hepatitis C, we assessed the efficacy of interferon alfa-2b (IFN) in preventing recurrent hepatit
66 value of outpatient interleukin-2 (IL-2) and interferon alfa-2b (IFN) relative to high-dose (HD) IL-2
68 C melanoma were randomly assigned to receive interferon alfa-2b (IFN-alpha-2b) 20 MIU/m(2) intravenou
69 ession-free survival (PFS) of bevacizumab or interferon alfa-2b (IFN-alpha-2b) added to octreotide am
71 tolerability of sorafenib administered with interferon alfa-2b (IFN-alpha-2b) as first- or second-li
72 estigated maintenance therapy with pegylated interferon alfa-2b (IFN-alpha-2b) in patients whose oste
73 d active specific immunotherapy and low-dose interferon alfa-2b (IFN-alpha-2b) with the OS achieved u
74 pe 1 virus (HCV) is dependent on the dose of interferon alfa-2b (IFN-alpha2b), the acute clearance of
76 reliminary efficacy of once-weekly pegylated interferon alfa-2b (IFNalpha-2b) in patients with advanc
78 Pivotal trial E1684 of adjuvant high-dose interferon alfa-2b (IFNalpha2b) therapy in high-risk mel
80 all available randomized clinical trials of interferon alfa-2b in patients with chronic hepatitis C.
81 en subsequently used it, in combination with interferon alfa-2b, in a second cohort of this study and
82 polypeptide of recombinant human albumin and interferon alfa-2b, in patients with chronic hepatitis C
84 conditions were normalized by treatment with interferon alfa-2b or after expression of wild-type DOCK
85 radical nephrectomy followed by therapy with interferon alfa-2b or to receive interferon alfa-2b ther
86 er inflammation to a greater extent than did interferon alfa-2b, particularly in subjects with sustai
89 riple therapy with boceprevir plus pegylated interferon alfa-2b (peginterferon) and ribavirin, which
90 on of therapy) than of patients who received interferon alfa-2b plus ribavirin (56 percent vs. 44 per
92 a-2a plus ribavirin was tolerated as well as interferon alfa-2b plus ribavirin and produced significa
93 stained virologic response, as compared with interferon alfa-2b plus ribavirin or peginterferon alfa-
95 ety of peginterferon alfa-2a plus ribavirin, interferon alfa-2b plus ribavirin, and peginterferon alf
97 hout adjuvant oral cimetidine and/or topical interferon alfa-2b provide satisfactory tumor control.
98 I trial of fluorouracil (FU) and recombinant interferon alfa-2b (rIFNalpha2b) in HCC was launched wit
100 mized trial evaluating the role of high-dose interferon alfa-2b therapy (HDI) or completion lymph nod
105 toxicity associated with adjuvant high-dose interferon-alfa-2b therapy (HDI) for high-risk melanoma
106 herapy with at least 2 million units (MU) of interferon alfa-2b three times weekly for 24 weeks.
107 itis C virus (HCV) were treated with 5 MU of interferon alfa-2b three times weekly for 6 months.
109 2a plus daily placebo, or 3 million units of interferon alfa-2b thrice weekly plus daily ribavirin fo
111 rogressive pulmonary metastasis resistant to interferon alfa-2b treatment 7 months after he underwent
113 in patients treated with CIFN (9 microg) and interferon alfa-2b was 7% and 0%, respectively (P = .03)
114 ation treatment of topical retinoic acid and interferon alfa-2b was effective in treating lesions wit
116 y for 24 weeks, and lower doses of pegylated interferon alfa-2b were less effective than standard dos
117 1.0, 1.5 microg/kg) the clinical efficacy of interferon alfa-2b while preserving its safety profile.
118 azine, decrescendo interleukin-2 (IL-2), and interferon alfa-2b with granulocyte-macrophage colony-st
WebLSDに未収録の専門用語(用法)は "新規対訳" から投稿できます。